Previous Close | 412.00 |
Open | 415.00 |
Bid | 0.00 x 0 |
Ask | 406.00 x 0 |
Day's Range | 404.00 - 416.00 |
52 Week Range | 243.50 - 416.00 |
Volume | |
Avg. Volume | 15,073 |
Market Cap | 5.514B |
Beta (5Y Monthly) | 1.00 |
PE Ratio (TTM) | 70.38 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.00 (0.50%) |
Ex-Dividend Date | Jul 01, 2024 |
1y Target Est | N/A |
WALTHAM, Mass., October 26, 2023--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, and Ypsomed AG (SIX: YPSN), the leading developer and manufacturer of injection and infusion systems for self-medication have signed a supply agreement for Ypsomed’s customizable YpsoMate 2.25 autoinjector pen device with a fill volume of 2.0 milliliters.